These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19891598)

  • 41. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).
    Boss C; Roch C
    Expert Opin Ther Pat; 2016; 26(3):409-15. PubMed ID: 26593218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nanomedicine and its application in treatment of microglia-mediated neuroinflammation.
    Baby N; Patnala R; Ling EA; Dheen ST
    Curr Med Chem; 2014; 21(37):4215-26. PubMed ID: 25039775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation.
    Hellyer S; Leach K; Gregory KJ
    Curr Opin Pharmacol; 2017 Feb; 32():49-55. PubMed ID: 27842256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apoptosis modulators in the therapy of neurodegenerative diseases.
    Deigner HP; Haberkorn U; Kinscherf R
    Expert Opin Investig Drugs; 2000 Apr; 9(4):747-64. PubMed ID: 11060707
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.
    Grupe M; Grunnet M; Bastlund JF; Jensen AA
    Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):187-200. PubMed ID: 25441336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.
    Thorne RG; Frey WH
    Clin Pharmacokinet; 2001; 40(12):907-46. PubMed ID: 11735609
    [TBL] [Abstract][Full Text] [Related]  

  • 47. On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies.
    Sarin H
    Recent Pat CNS Drug Discov; 2010 Nov; 5(3):239-52. PubMed ID: 20722627
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting apoptosis in neurological disease using the herpes simplex virus.
    Perkins D
    J Cell Mol Med; 2002; 6(3):341-56. PubMed ID: 12417051
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neural cell cycle dysregulation and central nervous system diseases.
    Wang W; Bu B; Xie M; Zhang M; Yu Z; Tao D
    Prog Neurobiol; 2009 Sep; 89(1):1-17. PubMed ID: 19619927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A role for fMRI in optimizing CNS drug development.
    Borsook D; Becerra L; Hargreaves R
    Nat Rev Drug Discov; 2006 May; 5(5):411-24. PubMed ID: 16604100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders.
    Gray NA; Zhou R; Du J; Moore GJ; Manji HK
    J Clin Psychiatry; 2003; 64 Suppl 5():3-17. PubMed ID: 12720479
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Target identification for CNS diseases by transcriptional profiling.
    Altar CA; Vawter MP; Ginsberg SD
    Neuropsychopharmacology; 2009 Jan; 34(1):18-54. PubMed ID: 18923405
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of the vasopressin system for the treatment of CNS diseases.
    Ryckmans T
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):538-47. PubMed ID: 20812145
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brain-derived neurotrophic factor as a drug target for CNS disorders.
    Pezet S; Malcangio M
    Expert Opin Ther Targets; 2004 Oct; 8(5):391-9. PubMed ID: 15469390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription.
    Tatton WG; Chalmers-Redman RM; Ju WY; Wadia J; Tatton NA
    J Neural Transm Suppl; 1997; 49():245-68. PubMed ID: 9266433
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AP-1 transcription factor complexes in CNS disorders and development.
    Pennypacker KR
    J Fla Med Assoc; 1995 Aug; 82(8):551-4. PubMed ID: 7561734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of inducible transcription factors in apoptotic nerve cell death.
    Dragunow M; Preston K
    Brain Res Brain Res Rev; 1995 Jul; 21(1):1-28. PubMed ID: 8547952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation.
    Kielian T; Drew PD
    J Neurosci Res; 2003 Feb; 71(3):315-25. PubMed ID: 12526021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. B-myb and C-myb play required roles in neuronal apoptosis evoked by nerve growth factor deprivation and DNA damage.
    Liu DX; Biswas SC; Greene LA
    J Neurosci; 2004 Oct; 24(40):8720-5. PubMed ID: 15470138
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 5-HT2C receptor modulators: a patent survey.
    Lee J; Jung ME; Lee J
    Expert Opin Ther Pat; 2010 Nov; 20(11):1429-55. PubMed ID: 20849206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.